hitting not likely disruptive cyclica attempting find individual compounds interact dozens target proteins avoid interacting hundreds proteins kurji explains currently development adds incorporation wealth anonymized global genetic data variations proteins software specify patients candidate drugs work best kurji claims features eventually able shave years typical seven year long time frame bringing candidate drug initial identification human trials merck bayer big pharma companies announced partnerships cyclica case ai pharma partnerships companies not releasing insight exactly ai generated drug candidates coming collaborations cyclica shared details successes identifying key target protein linked fda approved drugs systemic scleroderma autoimmune disease skin organs linked ebola